# World Journal of *Clinical Cases*

World J Clin Cases 2022 December 6; 10(34): 12462-12803





Published by Baishideng Publishing Group Inc

W J C C World Journal of Clinical Cases

#### Contents

Thrice Monthly Volume 10 Number 34 December 6, 2022

#### **FIELD OF VISION**

12462 Problematics of neurosurgical service during the COVID-19 pandemic in Slovenia Munda M, Bosnjak R, Velnar T

#### **MINIREVIEWS**

- 12470 Circulating angiotensin converting enzyme 2 and COVID-19 Leowattana W, Leowattana T, Leowattana P
- 12484 Evaluation of gut dysbiosis using serum and fecal bile acid profiles Monma T, Iwamoto J, Ueda H, Tamamushi M, Kakizaki F, Konishi N, Yara S, Miyazaki T, Hirayama T, Ikegami T, Honda A
- 12494 Pediatric kidney transplantation during the COVID-19 pandemic Tamura H

#### **ORIGINAL ARTICLE**

#### **Clinical and Translational Research**

12500 Coptis, Pinellia, and Scutellaria as a promising new drug combination for treatment of Helicobacter pylori infection

Yu Z, Sheng WD, Yin X, Bin Y

#### **Case Control Study**

12515 Effects of illness perception on negative emotions and fatigue in chronic rheumatic diseases: Rumination as a possible mediator

Lu Y, Jin X, Feng LW, Tang C, Neo M, Ho RC

#### **Retrospective Study**

12532 Significance of incidental focal fluorine-18 fluorodeoxyglucose uptake in colon/rectum, thyroid, and prostate: With a brief literature review

Lee H, Hwang KH

12543 Follow-up study on ThinPrep cytology test-positive patients in tropical regions

Chen YC, Liang CN, Wang XF, Wang MF, Huang XN, Hu JD

- 12551 Effect of teach-back health education combined with structured psychological nursing on adverse emotion and patient cooperation during 99mTc-3PRGD2.SPECT/CT Gong WN, Zhang YH, Niu J, Li XB
- Nosocomial infection and spread of SARS-CoV-2 infection among hospital staff, patients and caregivers 12559 Cheng CC, Fann LY, Chou YC, Liu CC, Hu HY, Chu D



World Journal of Clinical Cases

#### Contents

Thrice Monthly Volume 10 Number 34 December 6, 2022

#### **Observational Study**

- 12566 Effectiveness and safety of generic and brand direct acting antivirals for treatment of chronic hepatitis C Abdulla M, Al Ghareeb AM, Husain HAHY, Mohammed N, Al Qamish J
- 12578 Influence of group B streptococcus and vaginal cleanliness on the vaginal microbiome of pregnant women Liao Q, Zhang XF, Mi X, Jin F, Sun HM, Wang QX

#### **Randomized Controlled Trial**

12587 Clinical study on tri-tongue acupuncture combined with low-frequency electrical stimulation for treating post-stroke dysarthria

Man B, Li WW, Xu JF, Wang Q

#### **META-ANALYSIS**

12594 Three-dimensional time-of-flight magnetic resonance angiography combined with high resolution T2weighted imaging in preoperative evaluation of microvascular decompression

Liang C, Yang L, Zhang BB, Guo SW, Li RC

#### **CASE REPORT**

- 12605 Acute cytomegalovirus hepatitis in an immunocompetent patient: A case report Wang JP, Lin BZ, Lin CL, Chen KY, Lin TJ
- 12610 Long-term results of extended Boari flap technique for management of complete ureteral avulsion: A case report

Zhong MZ, Huang WN, Huang GX, Zhang EP, Gan L

12617 Amyloid  $\beta$ -related angiitis of the central nervous system occurring after COVID-19 vaccination: A case report

Kizawa M, Iwasaki Y

12623 Pseudoileus caused by primary visceral myopathy in a Han Chinese patient with a rare MYH11 mutation: A case report

Li N, Song YM, Zhang XD, Zhao XS, He XY, Yu LF, Zou DW

12631 Emergent use of tube tip in pharynx technique in "cannot intubate cannot oxygenate" situation: A case report Lin TC, Lai YW, Wu SH

12637 Inflammatory myofibroblastic tumor of the central nervous system: A case report Su ZJ, Guo ZS, Wan HT, Hong XY

- 12648 Atypical aggressive vertebral hemangioma of the sacrum with postoperative recurrence: A case report Wang GX, Chen YQ, Wang Y, Gao CP
- 12654 Closed reduction of hip dislocation associated with ipsilateral lower extremity fractures: A case report and review of the literature Xu Y, Lv M, Yu SO, Liu GP

	World Journal of Clinical Cases
Conten	ts Thrice Monthly Volume 10 Number 34 December 6, 2022
12665	Repair of a large patellar cartilage defect using human umbilical cord blood-derived mesenchymal stem cells: A case report
	Song JS, Hong KT, Song KJ, Kim SJ
12671	Abdominal bronchogenic cyst: A rare case report
	Li C, Zhang XW, Zhao CA, Liu M
12678	Malignant fibrous histiocytoma of the axilla with breast cancer: A case report
	Gao N, Yang AQ, Xu HR, Li L
12684	Rapid hemostasis of the residual inguinal access sites during endovascular procedures: A case report
	Kim H, Lee K, Cho S, Joh JH
12690	Formation of granulation tissue on bilateral vocal cords after double-lumen endotracheal intubation: A case report
	Xiong XJ, Wang L, Li T
12696	Giant cellular leiomyoma in the broad ligament of the uterus: A case report
	Yan J, Li Y, Long XY, Li DC, Li SJ
12703	Pomolidomide for relapsed/refractory light chain amyloidosis after resistance to both bortezomib and daratumumab: A case report
	Li X, Pan XH, Fang Q, Liang Y
12711	Ureteral- artificial iliac artery fistula: A case report
	Feng T, Zhao X, Zhu L, Chen W, Gao YL, Wei JL
12717	How to manage isolated tension non-surgical pneumoperitonium during bronchoscopy? A case report
	Baima YJ, Shi DD, Shi XY, Yang L, Zhang YT, Xiao BS, Wang HY, He HY
12726	Amiodarone-induced muscle tremor in an elderly patient: A case report
	Zhu XY, Tang XH, Yu H
12734	Surgical treatment of Pitt-Hopkins syndrome associated with strabismus and early-onset myopia: Two case reports
	Huang Y, Di Y, Zhang XX, Li XY, Fang WY, Qiao T
12742	Massive low-grade myxoid liposarcoma of the floor of the mouth: A case report and review of literature
	Kugimoto T, Yamagata Y, Ohsako T, Hirai H, Nishii N, Kayamori K, Ikeda T, Harada H
12750	Gingival enlargement induced by cyclosporine in Medullary aplasia: A case report
	Victory Rodríguez G, Ruiz Gutiérrez ADC, Gómez Sandoval JR, Lomelí Martínez SM
12761	Compound heterozygous mutations in PMFBP1 cause acephalic spermatozoa syndrome: A case report
	Deng TQ, Xie YL, Pu JB, Xuan J, Li XM
12768	Colonic tubular duplication combined with congenital megacolon: A case report
	Zhang ZM, Kong S, Gao XX, Jia XH, Zheng CN



Combon	World Journal of Clinical Cases
Conten	Thrice Monthly Volume 10 Number 34 December 6, 2022
12775	Perforated duodenal ulcer secondary to deferasirox use in a child successfully managed with laparoscopic drainage: A case report
	Alshehri A, Alsinan TA
12781	Complication after nipple-areolar complex tattooing performed by a non-medical person: A case report
	Byeon JY, Kim TH, Choi HJ
12787	Interventional urethral balloon dilatation before endoscopic visual internal urethrotomy for post-traumatic bulbous urethral stricture: A case report
	Ha JY, Lee MS
12793	Regression of gastric endoscopic submucosal dissection induced polypoid nodular scar after <i>Helicobacter pylori</i> eradication: A case report
	Jin BC, Ahn AR, Kim SH, Seo SY
12799	Congenital absence of the right coronary artery: A case report
	Zhu XY, Tang XH



## Contents

Thrice Monthly Volume 10 Number 34 December 6, 2022

#### **ABOUT COVER**

Editorial Board Member of World Journal of Clinical Cases, Giuseppe Lanza, MD, MSc, PhD, Associate Professor, Department of Surgery and Medical-Surgical Specialties, University of Catania, Catania 95123, Italy. glanza@oasi.en.it

#### **AIMS AND SCOPE**

The primary aim of World Journal of Clinical Cases (WJCC, World J Clin Cases) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

#### **INDEXING/ABSTRACTING**

The WJCC is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 Edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJCC as 1.534; IF without journal self cites: 1.491; 5-year IF: 1.599; Journal Citation Indicator: 0.28; Ranking: 135 among 172 journals in medicine, general and internal; and Quartile category: Q4. The WJCC's CiteScore for 2021 is 1.2 and Scopus CiteScore rank 2021: General Medicine is 443/826.

### **RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: Si Zhao; Production Department Director: Xu Guo; Editorial Office Director: Jin-Lei Wang.

NAME OF JOURNAL	INSTRUCTIONS TO AUTHORS
World Journal of Clinical Cases	https://www.wignet.com/bpg/gerinfo/204
<b>ISSN</b>	GUIDELINES FOR ETHICS DOCUMENTS
ISSN 2307-8960 (online)	https://www.wignet.com/bpg/GerInfo/287
LAUNCH DATE	GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
April 16, 2013	https://www.wignet.com/bpg/gerinfo/240
FREQUENCY	PUBLICATION ETHICS
Thrice Monthly	https://www.wignet.com/bpg/GerInfo/288
<b>EDITORS-IN-CHIEF</b> Bao-Gan Peng, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati, Ja Hyeon Ku	PUBLICATION MISCONDUCT https://www.wjgnet.com/bpg/gerinfo/208
EDITORIAL BOARD MEMBERS	ARTICLE PROCESSING CHARGE
https://www.wignet.com/2307-8960/editorialboard.htm	https://www.wignet.com/bpg/gerinfo/242
PUBLICATION DATE December 6, 2022	<b>STEPS FOR SUBMITTING MANUSCRIPTS</b> https://www.wjgnet.com/bpg/GerInfo/239
COPYRIGHT	ONLINE SUBMISSION
© 2022 Baishideng Publishing Group Inc	https://www.f6publishing.com

© 2022 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com



W J C C World Journal of Clinical Cases

Submit a Manuscript: https://www.f6publishing.com

World J Clin Cases 2022 December 6; 10(34): 12637-12647

DOI: 10.12998/wjcc.v10.i34.12637

ISSN 2307-8960 (online)

CASE REPORT

# Inflammatory myofibroblastic tumor of the central nervous system: A case report

Zhen-Jin Su, Ze-Shang Guo, Heng-Tong Wan, Xin-Yu Hong

Specialty type: Medicine, research and experimental

Provenance and peer review:

Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

#### Peer-review report's scientific quality classification

Grade A (Excellent): 0 Grade B (Very good): B, B Grade C (Good): C Grade D (Fair): D Grade E (Poor): 0

P-Reviewer: Cao X, China; Shalli K, United Kingdom

Received: June 30, 2022 Peer-review started: June 30, 2022 First decision: August 4, 2022 Revised: September 16, 2022 Accepted: November 7, 2022 Article in press: November 7, 2022 Published online: December 6, 2022



Zhen-Jin Su, Ze-Shang Guo, Heng-Tong Wan, Xin-Yu Hong, Department of Neurosurgical Oncology, The First Hospital of Jilin University, Changchun 130000, Jilin Province, China

Corresponding author: Xin-Yu Hong, PhD, Neurosurgeon, Professor, Department of Neurosurgical Oncology, The First Hospital of Jilin University, No. 71, Xinmin Street, Changchun City, Changchun 130000, Jilin Province, China. hongxy@jlu.edu.cn

## Abstract

#### BACKGROUND

An inflammatory myofibroblastic tumor (IMT) occurring in the central nervous system is very rare, and thus its pathogenesis is unknown. This case report and literature review aimed to explore the pathogenesis, clinical features, imaging findings, pathological characteristics, immunohistochemical characteristics, diagnoses, treatments, and risks of postoperative recurrence of IMT in the central nervous system.

#### CASE SUMMARY

A 67-year-old woman was admitted to the hospital with an exophthalmic protrusion and double vision in the left eye that had persisted for 3 mo. Magnetic resonance imaging (MRI) showed a 2.4 cm × 1.3 cm heterogeneous large mass in the bottom of the left anterior cranial fossa, which was closely related to the dura mater. Before surgery, we suspected the mass to be meningioma. The entire mass was successfully removed under neuronavigation and electrophysiological monitoring, and postoperative pathology indicated an IMT with extensive infiltration of chronic inflammatory cells and scattered multinucleated giant cells. Head MRI at the 3-mo follow-up showed that the tumor at the bottom of left anterior cranial fossa had been completely resected without recurrence.

#### **CONCLUSION**

From the histological, immunohistochemical, and genetic analyses, the present case suggests that the pathogenesis of IMT-CNS is related to autoimmunity.

Key Words: Inflammatory myofibroblastic tumor; Central nervous system; Pathogeny; Diagnosis; Treatment; Risk of postoperative recurrence; Case report

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** Inflammatory myofibroblastic tumors (IMTs) rarely occur in the central nervous system (CNS), and the pathogenesis of IMT-CNS is unknown. We present a 67-year-old woman with IMT-CNS who presented with an exophthalmic protrusion and double vision in the left eye lasting for 3 mo. A 2.4 cm  $\times$  1.3 cm mass was found by magnetic resonance imaging at the left anterior cranial fossa base, and postoperative pathology indicated an IMT. Histological, immunohistochemical, and genetic analyses indicated that the IMT-CNS pathogenesis may be autoimmunity related. The main treatments for INT-CNS are gross tumor resection or rituximab infusion combined with high-dose prednisone.

Citation: Su ZJ, Guo ZS, Wan HT, Hong XY. Inflammatory myofibroblastic tumor of the central nervous system: A case report. *World J Clin Cases* 2022; 10(34): 12637-12647 URL: https://www.wjgnet.com/2307-8960/full/v10/i34/12637.htm DOI: https://dx.doi.org/10.12998/wjcc.v10.i34.12637

#### INTRODUCTION

Inflammatory myofibroblastic tumors (IMTs) are characterized by proliferation of myofibroblastic spindle cells with mixed inflammatory infiltrates of plasma cells, lymphocytes, eosinophils, and histiocytes. While the most common site for these tumors is the lung in the form of a plasma cell granuloma, IMTs can occur in nearly every organ system, including the lung, liver, mesenteric system, gastrointestinal tract, retroperitoneum, urinary bladder, upper respiratory tract, and mediastinum. However, an IMT of the central nervous system (IMT-CNS) is an extremely rare disease[1,2].

IMTs were once referred to with diverse names such as inflammatory pseudotumor, plasma cell granuloma, pseudosarcomatous myofibroblastic proliferation, and inflammatory myofibrohistiocytic proliferation[3-5]. Then in 2002 the World Health Organization (WHO) classification of soft tissue tumors renamed these lesions as "inflammatory myofibroblastic tumors" and were allocated to the soft tissue tumor category. When the WHO revised the classification of soft tissue tumors in 2003 and again 2020, no changes were made regarding IMTs. However, in the latest 2021 WHO classification of CNS tumors, the content related to IMTs was revised to be consistent with that of soft tissue tumors. Recent studies have shown that nearly 50% of IMTs have clonal rearrangements of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase gene located on *2p23* and show immunohistochemical expression of the ALK protein[6].

Herein, we presented a case in which an IMT was found in the bottom left anterior cranial fossa. To better understand the pathological and radiological features of IMT-CNS as well as the relevant surgical treatment, adjuvant therapy, prognosis, and important different diagnoses, we also reviewed 49 cases of IMT-CNS reported in the literature since the year 2000.

#### CASE PRESENTATION

#### Chief complaints

A 67-year-old woman was admitted to the hospital for an exophthalmic protrusion and double vision in the left eye persisting for 3 mo.

#### History of present illness

The patient's symptoms had started 3 mo prior with an exophthalmic protrusion and double vision in the left eye.

#### History of past illness

The patient had no notable medical history.

#### Personal and family history

The patient had no notable personal and family history.

#### Physical examination

On physical examination, the patient had a temperature of 36.6 °C, heart rate of 93 bpm, respiratory rate of 16 breaths/min, blood pressure of 180/90 mmHg, and oxygen saturation in room air of 98%. The physical examination showed a fixed left eyeball, without any other pathological signs.

Zaisbidena® WJCC | https://www.wjgnet.com

#### Laboratory examinations

The preoperative complete blood count and coagulation results were all within normal ranges. Postoperative blood analysis revealed mild leukocytosis based on a leukocyte count of  $11 \times 10^{9}$ /L with predominantly neutrophils, a mildly reduced hemoglobin level of 113 g/L, a markedly elevated Creactive protein level of 180 mg/dL, and a normal procalcitonin level of 0.056 ng/mL. The erythrocyte sedimentation rate was also normal. Arterial blood gas analysis showed mild lactic acid accumulation and metabolic acidosis. Other test results including blood glucose, urine analysis, stool analysis and coagulation were all within normal ranges.

#### Imaging examinations

Computed tomography showed a hypointense mass in the bottom of the left anterior cranial fossa with a Computed tomography value of 45 HU. Magnetic resonance imaging (MRI) showed a large oval mass measuring 2.4 cm × 1.3 cm in the bottom of the left middle cranial fossa, with slight hyperintense signals on T1-weighted imaging (T1WI) and slightly hypointense signals on T2-weighted imaging (T2WI) (Figure 1A and B). Isointense signal was observed on the fluid attenuated inversion recovery image (Figure 1C). After gadolinium administration, obvious heterogenous enhancement was observed (Figure 1D). MRI showed significant compression displacement of the left optic nerve. No obvious restriction was observed on diffusion weighted imaging.

#### FINAL DIAGNOSIS

The results of pathological examination were suggestive of IMT. Hematoxylin and eosin-stained paraffin sections predominantly showed an IMT with extensive infiltration of chronic inflammatory cells and scattered multinucleated giant cells (Figure 2A and B). Immunohistochemical analysis indicated that the tumor was negative for ALK expression (Figure 2C). However, the specimen was positive for exponential moving average (Figure 2D), immunoglobulin G4 (IgG4, Figure 2E), vimentin (Figure 2F), smooth muscle actin, CD20, and Bcl-2 as well as negative for S-100, PR, and SSTR2. In addition, in situ hybridization showed negative results for Epstein-Barr virus (EBV)-encoded RNA.

#### TREATMENT

A preoperative clinical and radiological diagnosis of meningioma was made, and surgery was performed with preoperative neuronavigation and intraoperative neurophysiological monitoring. The tumor was located at the base of the anterior cranial fossa 3.5 cm away from the bone window. The tumor appeared kermesinus and tough with a clear boundary from the surrounding tissues. The basal part was adhered tightly to the base of the anterior cranial fossa and sellar tubercle. The tumor filled the entire left wing of the sphenoid bone and completely wrapped around the pituitary stalk, left optic nerve, left internal carotid artery, and left posterior communicating artery. The tumor was pushing the left oculomotor nerve outward. The tumor blood supply decreased significantly after the tumor base was severed. During surgery, the tumor was completely removed. The patient then developed oculomotor nerve palsy after surgery. Hence, we suspected anoculomotor schwannoma. Postoperative computed tomography (Figure 1E) showed that the lesion was completely resected, with no signs of residual tumor.

#### OUTCOME AND FOLLOW-UP

This patient was followed up at 3 mo after surgery. Head MRI showed that the tumor at the bottom left anterior cranial fossa had been completed resected without recurrence (Figure 1F). As the tumor was completely wrapped around the left optic nerve before surgery, the nerve was inevitably injured during surgery. On general medical examination, the vision of the left eye had improved to a level only slightly lower than that preoperation. The function of the left abducens nerve had recovered. In addition, headache and ophthalmalgia were completely resolved.

#### DISCUSSION

IMT in the CNS, as observed in the present case, is very rare. For the purpose of characterizing the features of this disease, we performed a literature review of IMT-CNS cases. We recorded and analyzed the data for all cases that met the inclusion criteria of ALK immunohistochemical staining and treatment involving surgical resection since 2000 based on the timing of the WHO definition. After reviewing the





DOI: 10.12998/wjcc.v10.i34.12637 Copyright ©The Author(s) 2022.

Figure 1 Magnetic resonance imaging. A: T1-weighted magnetic resonance imaging (MRI) image before the operation showed the left anterior fossa floor occupation (arrow); B: T2-weighted MRI before surgery showed the left anterior fossa floor occupation (arrow); C: MRI fluid attenuated inversion recovery sequence before operation showed the left anterior fossa floor occupation (arrow); D: Preoperative MRI enhancement sequence showed the left anterior fossa floor occupation (arrow); E: One week after the operation, the MRI enhanced sequence showed the left anterior fossa base occupation (arrow); F: Three months after surgery, MRI enhanced sequence showed the left anterior fossa floor occupation (arrow).

> literature related to IMT, we recorded the relevant data for 49 cases, which are presented in Table 1 in reverse chronological order.

> Among the 49 cases, 27 cases (55.1%) were treated by simple complete resection of the mass, 5 cases (10.2%) by simple partial resection of the mass, and the other 17 cases (34.7%) with comprehensive treatment. We found that the method of resection did not affect the recurrence of IMT (P = 0.521; Table 1). Postoperative immunohistochemical results showed that a total of 10 cases (20.4%) were ALK positive. A total of 9 cases (18.4%) experienced recurrence within 5 years after comprehensive treatment (Table 1). We observed that positive ALK expression in IMTs was associated with a higher recurrence rate (6/10) than negative ALK expression (1/14; P = 0.009).

#### Epidemiology

IMT is a type of mesenchymal neoplasm, which frequently occurs in the lung[5,7]. IMT most commonly affects children and young adults, with a median age at first onset of 36 years[5]. The youngest reported age at onset was 3 mo[8] (age range: 3 mo to 82 years). Among the 49 cases reviewed, the mean patient age at onset was 41.0 years (range: 7-82 years), and there were 24 male and 25 female patients. Among these patients, the presenting sites were the hemicerebrum (n = 26), cerebellum (n = 3), basis cranii (n = 1) 6), ventricle (n = 5), cavernous sinus (n = 3), and other CNS sites (n = 6; Table 1). By comparison, our patient was a 67-year-old woman who had an IMT in the bottom of the left anterior cranial fossa, and thus this case was extremely rare.

#### Pathogenesis

The exact pathogenesis of IMT remains unclear to date. Some authors have suggested that the disease is related to bacterial and viral infections such as EBV and human herpesvirus[6,9,10]. However, EBV and human herpesvirus type 8 were negative in the majority of cases. In the report by Haüsler *et al*[11], PCR analysis of the patient's cerebrospinal fluid proved negative for Mycobacteria, herpes simplex virus, varicella-zoster virus, the human neurotropic polyomavirus JC, EBV, human herpesvirus type 6, and human herpesvirus type 8. The majority of our reviewed cases also showed no viral infection. However, these negative findings do not rule out a viral etiology, as it is possible the viral load may have been too low, viruses not being specifically investigated may be involved, and viruses may have triggered inflammatory or even neoplastic processes before being eliminated from the brain tissue[11-13]. Some



#### Table 1 Summary of 49 cases of inflammatory myofibroblastic tumor of the central nervous system reported in the literature since 2000

Ref.	Age in yr/sex	Duration of symptom in mo	Main symptoms and signs	Location	Contrast enhancement	Tumor diameter in cm	ALK expression	Main treatment	Chemotherapy	Prognosis
Present case	67/F	3	Diplopia	Left middle cranial fossa	Intense	2.4	Negative	GTR	None	No recurrence
Wang <i>et al</i> [ <mark>5</mark> ], 2019	21/F	0.5	Blurred vision	Right frontal lobe	Intense	10.0	Negative	GTR	None	No recurrence
Wang <i>et al</i> [5], 2019	60/M	N/A	Gait disturbance	Cerebellar hemisphere	Intense	N/A	Negative	GTR	None	No recurrence
Wang <i>et al</i> [ <mark>5</mark> ], 2019	48/F	Several	Paranoid	Right temporal lobe	Intense	5.3	Negative	GTR	None	No recurrence
Wang <i>et al</i> [ <mark>5</mark> ], 2019	20/F	0.75	Headache	Right temporal lobe	Intense	5.0	Positive	GTR	None	7 mo after 1st surgery
Wang <i>et al</i> [ <mark>5</mark> ], 2019	82/F	6	Memory decrease	Right temporal lobe	Intense	N/A	N/A	GTR	None	No recurrence
Wang <i>et al</i> [ <mark>5</mark> ], 2019	51/F	1.5	Headache	Cerebellar hemisphere	Intense	N/A	N/A	Biopsy	Steroid	N/A
Kuang <i>et al</i> [ <mark>5</mark> ], 2016	53/M	12	Blurred vision	Pineal	Intense	N/A	N/A	GTR	None	No recurrence
PascualGallego et al[7], 2013	47/F	N/A	Headache	Left temporooc- cipital lobe	Intense	N/A	Negative	GTR	None	4 mo after 1st surgery
Denis <i>et al</i> [ <mark>19</mark> ], 2013	26/M	3	Headache, blurred vision	Left frontal lobe	Intense	2.0	Positive	GTR	None	2 mo after 1st surgery
Denis <i>et al</i> [ <mark>19</mark> ], 2013	17/F	N/A	Seizures	Left frontal lobe	N/A	N/A	Positive	GTR	None	2.5 yr after 1st surgery
Denis <i>et al</i> [ <mark>19</mark> ], 2013	65/F	N/A	Blurred vision	Occipital lobe	Intense	5.0	Negative	STR	None	No recurrence
Denis <i>et al</i> [ <mark>19</mark> ], 2013	43/M	6	Headache	Orbit	Intense	N/A	Negative	GTR	None	No recurrence
Denis <i>et al</i> [ <mark>19</mark> ], 2013	7/M	N/A	N/A	Right temporal fossa	N/A	2.0	Positive	GTR	None	1.5 yr after 1st surgery
Denis <i>et al</i> [ <mark>19</mark> ], 2013	24/M	N/A	N/A	Left temporal lobe	N/A	N/A	Positive	GTR	None	2 yr after 1st surgery
Kolenc <i>et al</i> [ <mark>18</mark> ], 2013	77/F	N/A	Right partial motoric seizures	Left temporal lobe	Intense	N/A	Negative	Biopsy	Corticosteroids	No recurrence
Moss <i>et al</i> <b>[14]</b> , 2012	36/F	N/A	Diplopia	Left middle cranial fossa	Intense	N/A	Negative	STR	Corticosteroids	24 mo after 1st surgery
Moss <i>et al</i> [ <mark>14</mark> ], 2012	50/F	5	Headache	Cavernous sinus	Intense	N/A	Negative	Steroid	None	N/A
Kato <i>et al</i> [ <mark>28</mark> ], 2011	60/M	N/A	Gait disturbance	Cerebellar	Intense	1.8	Negative	GTR	None	No recurrence
de Oliveira <i>et</i> al[27], 2009	7/M	3	Headache	Right temporal fossa	Intense	4.0	Positive	GTR	None	24 mo after 1st surgery
Lui <i>et al</i> [ <mark>2</mark> ], 2009	60/F	N/A	Blurred vision	Cerebral falx	Intense	N/A	Negative	GTR	Radiation therapy	No recurrence
Lui <i>et al</i> [ <mark>2</mark> ], 2009	52/F	N/A	N/A	Right ventricle	Intense	N/A	Negative	GTR	None	No recurrence
Lui et al <mark>[2]</mark> , 2009	45/M	N/A	Left-sided weakness	Right frontal lobe	N/A	N/A	Negative	GTR	None	No recurrence
Lui <i>et al</i> [ <mark>2</mark> ], 2009	26/F	6	Blurred vision	Left occipital lobe	Intense	N/A	Negative	Biopsy	Corticosteroids, thalidomide	No recurrence
Swain <i>et al</i> [ <mark>6</mark> ], 2008	8/M	N/A	Attention deficiency	Left temporal lobe	Intense	N/A	Negative	STR	None	No recurrence



#### Su ZJ et al. IMT of CNS

SeaterJerkN/AStatureLeft orcirital tabutoIntense08PositiveGTRNoneNecessman Research ResearchSooin of all Sooin of all <br< th=""><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th></br<>											
Senair eff Senair eff Senai	Swain <i>et al</i> [ <mark>6</mark> ], 2008	28/F	N/A	Seizure	Left occipital lobe	Intense	0.8	Positive	GTR	None	No recurrence
Second off         N/A         N/A         N/A         OTH         Nome         Nomemory constraints           Second off         7/4         N/A         Headach, Right parietal         N/A         3.8         T.M         Nome         Nomemory constraints           Second off         0/A         N/A         Second off         N/A         N/A         Second off         Nome         Nome         Nomemory constraints           Second off         0/A         N/A         Second off         N/A	Swain <i>et al</i> [6], 2008	30/M	N/A	Headache	Posterior fossa	N/A	N/A	Negative	GTR	Radiation therapy	No recurrence
Second allo,         7/F         N/A         Headbach         Bight paraietal         N/A         3.8         GR         None         None-restored Non-second allo,           Stored allo,         0.8/F         N/A         Scharer sec         N/A         S4         GR         None         None-restored None-restored           Miyahara et all         S/M         N/A         Mach         N/A         N/A         N/A         N/A         GR         Stored         None-restored           Miyahara et all         S/M         N/A         Mach         Paracele         N/A         N/A         N/A         GR         Stored         None-restored           Miyahara et al         S/M         N/A         MAC         Paracele         N/A         N/A         N/A         Stored         Robit contract           Miyahara et al         S/M         N/A         N/A         N/A         N/A         N/A         N/A         Stored         Robit contract           Miyahara et al         S/M         N/A         Readehe         Paracele         N/A         N/A         N/A         Stored         Robit contract           Miyahara et al         S/M         N/A         Neadehe         Paracele         N/A         N/A	Swain <i>et al</i> [6], 2008	31/F	1	Headache	Right frontal lobe	N/A	N/A	N/A	GTR	None	No recurrence
Souin et al[-], 2008     0.8/F     N/A     Seizures     Right lemporal base     N/A     8.4     CIR     Nome     Necurrence for currence (and possible)       Miyahan et al Miyahan et al Mixahan et al Miyahan et al Miyahan et al Miyahan et al Miyahan et al Miyahan et al Mixahan et al Mixa	Swain <i>et al</i> [ <mark>6</mark> ], 2008	74/F	N/A	Headache, seizures	Right parietal lobe	N/A	3.8		GTR	None	No recurrence
Myspane at (2),200873/M1.Gaitanone disturbanceParaceleN/AN/AN/AGTRSteroidDied of completeMyspane at (3),200848/MN/AMemory decreaseParaceleN/AN/AN/AGTRSteroidNo completeMyspane at (3),200818/MN/AN/AParaceleN/AN/AN/AGTRSteroidNo compressionMyspane at (3),200863/FN/AHeadacheParaceleN/AN/AN/AGTRSteroidNo compressionMyspane at at (2),200863/FN/AHeadacheParaceleN/AN/AN/AGTRSteroidNo comperssionMyspane at at (2),200863/FN/AHeadacheParaceleN/AN/AN/AGTRSteroidNo comperssionMyspane at at (2),200863/M0.3BlepharoptosisLef orbit, caremous simusInterse1.5NegativeBiopsyCoticosteroidRegression2005 cf1131/MN/APleadacheCaremous simusInterseN/ANgativeGTRNoneNo caremous2005 cf1131/MN/AN/ATemporal and romal adosInterseN/ANegativeGTRNoneNo caremous2005 cf112/MN/AN/ASeluresInterseN/ANegativeGTRNoneNo caremous2005 cf112/MN/AN/ASeluresInt	Swain <i>et al</i> [ <mark>6</mark> ], 2008	0.8/F	N/A	Seizures	Right temporal lobe	N/A	8.4		GTR	None	No recurrence
Mityphane et al (20), 2008     48/M     N/A     Memory decrease     Paracele     N/A     N/A     N/A     GTR     Steroid     No recurrence       Mityphane et al (20), 2008     18/M     N/A     N/A     N/A     N/A     N/A     GTR     Steroid     No recurrence       Mityphane et al (20), 2008     63/F     N/A     Ideadache     Paracele     N/A     N/A     N/A     GTR     Steroid     No recurrence       Mityphane et al (20), 2008     63/F     N/A     Ideadache     Paracele     N/A     N/A     N/A     GTR     Steroid     Pargressin recurrence       Door et al[1], 2005     31/M     N/A     Jiegharoptosis     Left orbit, cavernous sims     Intense     1.5     Negative     GTR     None     No recurrence       Jeon et al[1], 2005     31/M     N/A     Jiegharoptosis     Cavernous sinus     Intense     1.5     Negative     GTR     None     No recurrence       Jeon et al[1], 2005     31/M     N/A     Jiegharoptosis     Cavernous sinus     Intense     N/A     Negative     GTR     No     No recurrence       Jeon et al[1], 2005     21/M     N/A     Aphasia     Temporal and fronial lobes     Intense     N/A     Negative     GTR     No     No recurrence   <	Miyahara <i>et al</i> [ <mark>20]</mark> , 2008	73/M	1	Gait disturbance	Paracele	N/A	N/A	N/A	GTR	Steroid	Died of complications
Mysphare et al [20], 200818/MN/AN/AParaceleN/AN/AN/AGTRSteroidNo recurrenceMysphare et al [20], 200867/FN/AHeadacheParaceleN/AN/AN/AGTRSteroidNo recurrenceMysphare et al [20], 200850/H0.3BlepharoptosiIct orbit, cavernoous sinusIntense1.5NogativeBiopsyCorticosteroidIpogressi200543/MN/ADizzinessOrbit, fak, sup. cavernoous sinusN/AN/ANegativeGTRNoneNo recurrence200531/MN/AHeadache, ptosisCavernoous sinusIntense1.5NegativeGTRNoneNo recurrence200541/MN/AN/APreporal lobeIntenseN/ANegativeSTRNoneNo recurrence200520041/MN/AAphasiaTemporal and frontal lobesIntenseN/ANegativeSTRNoneNo recurrence2005200510/MN/AAphasiaTemporal and frontal lobesIntenseN/ANegativeSTRNoneNo recurrence2005200411/L10/MN/AAphasiaIntenseN/ANegativeGTRNoneNo recurrence2005200510/HN/ASizaresCorbital lobeIntenseN/ANegativeGTRNo NoNo recurrence20052005	Miyahara <i>et al</i> [ <mark>20]</mark> , 2008	48/M	N/A	Memory decrease	Paracele	N/A	N/A	N/A	GTR	Steroid	No recurrence
Nytophane ard (20), 2008         63/F         N/A         Headache         Paracele         N/A         N/A         N/A         GTR         Steroid         Normation (2003)           Mytophane ard (20), 2008         50/M         0.3         Bepharoptos         Let orbit, fall, sup, suptimized (2003)         N/A         Negative         Biopsy         Corticosteroid         Registrice         Registrice         STR         Corticosteroid         Registrice         Registrice         STR         Corticosteroid         Registrice         Registrice         STR         Corticosteroid         Registrice         Registrice         STR         Corticosteroid         Registrice         STR         None         Registrice         Registrice         STR         None         Registrice         Registrice         STR         None         Registrice         Registrice         STR         None         Registrice         Registrice         Registrice         STR         None         Registrice         Registrice         Registrice         STR         None         Streadistrice         Regist	Miyahara <i>et al</i> [ <mark>20]</mark> , 2008	18/M	N/A	N/A	Paracele	N/A	N/A	N/A	GTR	Steroid	No recurrence
Miyahana et al       SV/M       S3       Blepharoptosis       Left orbit, cavernous sinus       Intense       1.5       Negative       Biopsy       Corticosteroids       Progressis         Jeon et al[1],       43/M       N/A       Dizziness       Orbit, falx, sup, tentorium       N/A       Negative       STR       Corticosteroids       Izy rafter         Jeon et al[1],       31/M       N/A       Pleadache, ptosis       Cavernous sinus       Intense       1.5       Negative       STR       Corticosteroids       No         Jeon et al[1],       41/M       N/A       N/A       Cavernous sinus       Intense       1.5       Negative       STR       None       No         Jeon et al[1],       41/M       N/A       N/A       Recorner, ptosis       Intense       N/A       Negative       STR       None       No         Jeon et al[1],       29/M       N/A       Aphasia       Temporal and frontal lobes       Intense       N/A       Negative       STR       None       No         Jeon et al[1],       29/M       N/A       N/A       Subdura       Intense       N/A       Negative       STR       None       No       recurrence         Jeon et al[1],       52/F       N/A       Sc	Miyahara <i>et al</i> [ <mark>20]</mark> , 2008	63/F	N/A	Headache	Paracele	N/A	N/A	N/A	GTR	Steroid	No recurrence
Jeon et al[1], 200543/MN/ADizznessOrbit, falx, sup, sugital sinus, itenioriumN/AN/ANegativeSTRCorticosteroids12 yr after surgeryJeon et al[1], 200531/MN/AHeadache, ptosisCavernous sinusIntense1.5NegativeGTRNoneNo recurrenceJeon et al[1], 200541/MN/AN/ATemporal lobeIntenseN/ANegativeSTRNoneNo recurrenceJeon et al[1], 200541/MN/AAphasiaTemporal and frontal lobesIntenseN/ANegativeStreoidNoneNo recurrenceJeon et al[1], 200529/MN/AAphasiaTemporal and frontal lobesIntenseN/ANegativeStreoidNoneNo recurrenceJeon et al[1], 200529/MN/AAphasiaTemporal and frontal lobeIntenseN/ANegativeStreoidNoneNo recurrenceJeon et al[1], 200520/MN/AN/ASeizuresFrontal lobeIntense5.0NegativeGTRNoneNo recurrenceJeon et al[1], 200520/FN/AN/ADiplopiaOrbitIntenseN/ANegativeGTRNoneNo recurrenceJeon et al[1], 200520/FN/AN/AOrbitIntenseN/ANegativeGTRNoneNo recurrenceJeon et al[1], 200520/FN/AN/AOrbitIntenseN	Miyahara <i>et al</i> [20], 2008	50/M	0.3	Blepharoptosis	Left orbit, cavernous sinus	Intense	1.5	Negative	Biopsy	Corticosteroids	Progressive reduction
Jeon et al[1], 200531/MN/AHeadache, ptosisCavernous sinusIntense1.5NegativeGTRNoneNe recurrenceJeon et al[1], 200541/MN/AN/ATemporal lobeIntenseN/ANegativeSTRNoneNo recurrenceJeon et al[1], 200529/MN/AAphasiaTemporal and frontal lobesIntenseN/ANegativeSteroidNoneNo recurrenceJeon et al[1], 200542/MN/AAphasiaTemporal and frontal lobeIntenseN/ANegativeGTRNoneNo recurrenceJeon et al[1], 200550/MN/ASeizuresFrontal lobeIntenseN/ANegativeGTRNoneNo recurrenceJeon et al[1], 200550/MN/ASeizuresCocipital lobeIntenseN/ANegativeGTRNoneNo recurrenceJeon et al[1], 200552/FN/ASeizuresOccipital lobeIntenseN/ANegativeGTRNoneNo recurrenceJeon et al[1], 200565/FN/AN/AOccipital lobeIntenseN/ANegativeGTRNoneNo recurrenceJeon et al[1], 200503HeadacheLeft temporal lobeIntenseN/ANegativeGTRNoneNo recurrenceJeon et al[1], 200503HeadacheLeft temporal lobeIntenseN/AN/ASTRCoricosteroidDranatic decrese	Jeon <i>et al</i> [ <b>1</b> ], 2005	43/M	N/A	Dizziness	Orbit, falx, sup. sagittal sinus, tentorium	N/A	N/A	Negative	STR	Corticosteroids	12 yr after 1st surgery
Jeon et al[1], 200541/MN/AN/ATemporal lobeIntenseN/ANegativeSTRNoneNegeure of recurrenceJeon et al[1], 200529/MN/AAphasiaTemporal and frontal lobesIntenseN/ANegativeSteroidNoneNo recurrenceJeon et al[1], 200542/MN/AN/ASubduraIntenseN/ANegativeGTRNoneNo recurrenceJeon et al[1], 200550/MN/ASeizuresFrontal lobeIntenseN/ANegativeGTRNoneNo recurrenceJeon et al[1], 200550/MN/ASeizuresFrontal lobeIntenseN/ANegativeGTRNoneNo recurrenceJeon et al[1], 200550/MN/ASeizuresCocipital lobeIntenseN/ANegativeGTRNoneNo recurrenceJeon et al[1], 200524/FN/ADiplopiaOrbitIntenseN/ANegativeGTRNoneNo recurrenceJeon et al[1], 200524/FN/AN/AOccipital lobeIntenseN/ANegativeGTRNoneNo recurrenceJeon et al[1], 200524/FN/AN/AOccipital lobeIntenseN/ANegativeGTRNoneNo recurrenceJeon et al[1], 20050.3HeadacheLeft temporal lobeIntenseN/AN/AN/ASTRNoneNo recurrenceJeon et al[1], 200	Jeon <i>et al</i> [ <b>1</b> ], 2005	31/M	N/A	Headache, ptosis	Cavernous sinus	Intense	1.5	Negative	GTR	None	No recurrence
Jeon et al[1], 200529/MN/AAphasiaTemporal and frontal lobesIntenseN/ANegativeSteroidNoneNo recurrenceJeon et al[1], 200550/MN/AN/ASubduraIntenseN/ANegativeGTRNoneNo recurrenceJeon et al[1], 200550/MN/ASeizuresFrontal lobeIntense5.0NegativeGTRNoneNo recurrenceJeon et al[1], 200552/FN/ASeizuresCocipital lobeIntenseN/ANegativeGTRNoneNo recurrenceJeon et al[1], 200552/FN/ASeizuresOccipital lobeIntenseN/ANegativeGTRNoneNo recurrenceJeon et al[1], 200552/FN/ADiplopiaOrbitIntenseN/ANegativeGTRNoneNo recurrenceJeon et al[1], 200565/FN/AN/AOccipital lobeIntenseA/ANegativeGTRNoneNo recurrenceJeon et al[1], 20050.3HeadacheLeft temporal lobeIntenseN/AN/ASTRCorticosteroidsDramatic decrease in the massesJeonse et al [1], 2003N/AN/ASeizuresLeft temporal lobeN/AN/AN/ASTRNoneNo recurrenceHausler et al [1], 200315/MN/ASeizuresOccipital lobeIntenseN/AN/ASTRRadiation the rapyNo recurr	Jeon <i>et al</i> [1], 2005	41/M	N/A	N/A	Temporal lobe	Intense	N/A	Negative	STR	None	No recurrence
Jeon et al[1], 200542/MN/AN/ASubduraIntenseN/ANegativeGTRNoneNo recurrenceJeon et al[1], 200550/MN/ASeizuresFrontal lobeIntense5.0NegativeSTRNoneNo recurrenceJeon et al[1], 200552/FN/ASeizuresOccipital lobeIntenseN/ANegativeGTRNoneNo recurrenceJeon et al[1], 200524/FN/ADiplopiaOrbitIntenseN/ANegativeGTRNoneNo recurrenceJeon et al[1], 200565/FN/ADiplopiaOrbitIntense4.0NegativeGTRNoneNo recurrenceJeon et al[1], 200565/FN/AN/AOccipital lobeIntense4.0NegativeGTRNoneNo recurrenceJeon et al[1], 200565/FN/AN/AOccipital lobeIntenseN/AN/ASTRCorticosteroidsDramatic recurrenceJeon et al[1], 20050.3HeadacheLeft temporal lobeIntenseN/AN/ASTRNoneNo recurrenceInduster et al [11], 2003N/AN/ASeizuresOccipital lobeIntenseN/AN/ASTRNoneNo recurrenceHausler et al [11], 200315/MN/ASeizuresOccipital lobeIntenseN/AN/ASTRRadiation therapyNo recurrenceHausler et al [11], 2003	Jeon <i>et al</i> [1], 2005	29/M	N/A	Aphasia	Temporal and frontal lobes	Intense	N/A	Negative	Steroid	None	No recurrence
Jeon et al[1], 200550/MN/ASeizuresFrontal lobeIntense5.0NegativeSTRNoneNo recurrenceJeon et al[1], 200552/FN/ASeizuresOccipital lobeIntenseN/ANegativeGTRNoneNo recurrenceJeon et al[1], 200524/FN/ADiplopiaOrbitIntenseN/ANegativeGTRNoneNo recurrenceJeon et al[1], 200565/FN/AN/AOrbitIntenseN/ANegativeGTRNoneNo recurrenceJeon et al[1], 200565/FN/AN/AOccipital lobeIntense4.0NegativeGTRNoneNo recurrenceJeon et al[1], 200565/FN/AN/AOccipital lobeIntense4.0NegativeGTRNoneNo recurrenceJeon et al[1], 10, 200463/FN/AN/AOccipital lobeIntenseN/AN/ASTRCorticosteroidsDramatic recurrenceRoche et al [10], 2004N/AN/ASeizuresLeft temporal lobeN/AN/AN/ASTRNoneNo recurrenceHausler et al [11], 2003N/AN/ASeizuresCocipital lobeIntenseN/AN/ASTRNoneNo recurrenceHausler et al [11], 200315/MN/ASeizuresCocipital lobeIntense6.0PositiveGTRNone20 mo afte recurrenceHausler et al [11	Jeon <i>et al</i> [1], 2005	42/M	N/A	N/A	Subdura	Intense	N/A	Negative	GTR	None	No recurrence
Jeon et al[1], 200552/FN/ASeizuresOccipital lobeIntenseN/ANegativeGTRNoneNo recurrenceJeon et al[1], 200524/FN/ADiplopiaOrbitIntenseN/ANegativeGTRNoneNo recurrenceJeon et al[1], 200565/FN/AN/AOccipital lobeIntense4.0NegativeGTRNoneNo recurrenceJeon et al[1], 200565/FN/AN/AOccipital lobeIntense4.0NegativeGTRNoneNo recurrenceJeon et al[1], 20050.3HeadacheLeft temporal lobeIntenseN/AN/AN/ASTRCorticosteroids the mass seHausler et al [11], 2003N/A/MN/ASeizuresLeft temporal lobeN/AN/AN/ASTRNoneNo recurrenceHausler et al [11], 200315/MN/ASeizuresOccipital lobeIntenseN/AN/ASTRRadiation therapyNo recurrenceHausler et al [11], 200315/MN/ASeizuresOccipital lobeIntenseN/AN/ASTRRadiation therapyNo recurrenceHausler et al [11], 200315/MN/ASeizuresOccipital lobeIntenseN/AN/ASTRRadiation therapyNo recurrenceHausler et al [11], 200317/FN/AHeadacheLeft frontal lobeIntense6.0PositiveGTRNone<	Jeon <i>et al</i> [1], 2005	50/M	N/A	Seizures	Frontal lobe	Intense	5.0	Negative	STR	None	No recurrence
Jeon et al[1], 200524/FN/ADiplopiaOrbitIntenseN/ANegativeGTRNoneNo recurrenceJeon et al[1], 200565/FN/AN/AOccipital lobeIntense4.0NegativeGTRNone7 yr after surgeryRoche et al [10], 200420/F0.3HeadacheLeft temporal lobeIntenseN/AN/ASTRCorticosteroidsDramatic 	Jeon <i>et al</i> [1], 2005	52/F	N/A	Seizures	Occipital lobe	Intense	N/A	Negative	GTR	None	No recurrence
Jeon et al[1], 200565/FN/AN/AOccipital lobeIntense4.0NegativeGTRNone7 yr after surgeryRoche et al [10], 200420/F0.3HeadacheLeft temporal lobeIntenseN/AN/ASTRCorticosteroids decrease in the mass streementHausler et al 	Jeon <i>et al</i> [ <b>1</b> ], 2005	24/F	N/A	Diplopia	Orbit	Intense	N/A	Negative	GTR	None	No recurrence
Roche et al [10], 200420/F0.3Headache left temporal lobeIntenseN/AN/ASTRCorticosteroids decrease in the mass seHausler et al [11], 2003N/A/MN/ASeizuresLeft temporal 	Jeon <i>et al</i> [1], 2005	65/F	N/A	N/A	Occipital lobe	Intense	4.0	Negative	GTR	None	7 yr after 1st surgery
Hausler et al [11], 2003N/A/MN/ASeizuresLeft temporal lobeN/AN/ANegativeSTRNoneNo recurrenceHausler et al [11], 200315/MN/ASeizuresOccipital lobeIntenseN/AN/ASTRRadiation therapyNo recurrenceHausler et al 	Roche <i>et al</i> [10], 2004	20/F	0.3	Headache	Left temporal lobe	Intense	N/A	N/A	STR	Corticosteroids	Dramatic decrease in the mass size
Hausler et al [11], 200315/MN/ASeizuresOccipital lobeIntenseN/AN/ASTRRadiation therapyNo recurrenceHausler et al [11], 200317/FN/AHeadacheLeft frontal lobeIntense6.0PositiveGTRNone20 mo after 1st surgerBuccoliero et al [9], 200370/M6Partial loss of visionThe bottom of the frontal lobesIntense2.0NegativeBiopsyCorticosteroids, radiation 	Hausler <i>et al</i> [11], 2003	N/A/M	N/A	Seizures	Left temporal lobe	N/A	N/A	Negative	STR	None	No recurrence
Hausler et al [11], 200317/FN/AHeadacheLeft frontal lobeIntense6.0PositiveGTRNone20 mo after 1st surgerBuccoliero et al [9], 200370/M6Partial loss of visionThe bottom of the frontal lobesIntense2.0NegativeBiopsyCorticosteroids, radiation 	Hausler <i>et al</i> [11], 2003	15/M	N/A	Seizures	Occipital lobe	Intense	N/A	N/A	STR	Radiation therapy	No recurrence
Buccoliero <i>et al</i> 70/M 6 Partial loss of vision the frontal lobes 2.0 Negative Biopsy Corticosteroids, No remission radiation therapy	Hausler <i>et al</i> [11], 2003	17/F	N/A	Headache	Left frontal lobe	Intense	6.0	Positive	GTR	None	20 mo after 1st surgery
	Buccoliero <i>et al</i> [9], 2003	70/M	6	Partial loss of vision	The bottom of the frontal lobes	Intense	2.0	Negative	Biopsy	Corticosteroids, radiation therapy	No remission

ALK: Anaplastic lymphoma kinase; F: Female; GTR: Gross total resection; M: Male; N/A: Not available; STR: Subtotal resection.

patients had pulmonary nodules prior to the discovery of intracranial space-occupying lesions, and we believe that the occurrence of IMT may be associated with such lesions[4]. Because some researchers discovered polyclonal hypergammaglobulinemia, hyper-leukocytosis, and an increased sedimentation rate in some cases, it is also believed that IMT is an immune-related disorder[10,13,14]. Accordingly, corticosteroids have been used in IMT treatment. Post-traumatic or post-surgical mechanisms have also



12642



DOI: 10.12998/wjcc.v10.i34.12637 Copyright ©The Author(s) 2022.

Figure 2 Pathological section. A: Magnification of hematoxylin-eosin staining pathological section (× 100); B: Magnification of hematoxylin-eosin staining pathological section (× 400); C: Immunohistochemical anaplastic lymphoma kinase of tumor pathological section (magnification × 400); D: Immunohistochemical exponential moving average of tumor pathological section (magnification × 400); E: Tumor pathological section immunohistochemical immunoglobulin G4 (magnification × 400); F: Immunohistochemical vimentin of tumor pathological section (magnification × 400).

been proposed without convincing evidence<sup>[10,13]</sup>.

#### Clinical manifestations

Primary intracranial IMT is associated with a variety of clinical manifestations, mainly related to tumor location, size, relationship with surrounding tissues, and degree of edema. In the cases we reviewed, clinical symptoms included headache (n = 6, 35.3%), blurred vision (n = 5, 29.4%), ptosis (n = 2, 11.8%), seizure (n = 2, 11.8%), attention deficiency (n = 1, 5.9%), diplopia (n = 1, 5.9%), and dizziness (n = 1, 1.8%), attention deficiency (n5.8%). The average duration of clinical symptoms was 2.7 mo (range, 9 d to 6 mo). The duration of the clinical presentation in our patient matched that reported in the literature. Unusual clinical signs including polyclonal hypergammaglobulinemia, hyperleukocytosis, and increased sedimentation rate have been reported in some studies[10]. Hence, it is advisable to screen for these during clinical evaluation. In our case report, the patient's major complaint was exophthalmic protrusion and double vision, suggesting a mass in the bottom left middle cranial fossa.

#### Imaging features

After reviewing the previous literature, we found that IMT-CNS presents diverse results on T1WI, with most presenting isointense or hyperintense signals in T2WI[1,3,5,10,13-15]. The relative hypointensity of these lesions on T2WI, as seen in our case, can probably be attributed to the decreased free water content and is associated with a lack of mobile protons relative to a high degree of fibrosis and an elevated cellularity or high nucleus-to-cytoplasm ratio[16,17]. In most of the reviewed cases, heterogenous enhancement was observed after gadolinium administration. Our patient's findings were consistent with the aforementioned findings. According to Häusler et al[11], the anatomical location is highly variable, with meningeal lesions being the most frequently encountered type. Some authors believe that IMT originates in the dura mater[2,13]. Lesions in approximately 28% of cases showed local



thickening and/or radiologic enhancement of the dura mater [3,6,18], and this is consistent with our findings.

#### Diagnosis

IMT can occur in virtually every organ system, but intracranial cases are extremely rare[1,9]. There is no gold standard diagnostic marker yet for IMT, and diagnosis is currently mainly dependent on a combination of histological examination, immunohistochemical analysis, and molecular genetic analyses. In general, IMTs consist of a large number of myofibroblastic spindle cells with mixed inflammatory infiltrates of plasma cells, lymphocytes, eosinophils, multinuclear giant cells, and histiocytes[1,6, 19,20]. These cells coexist in a collagen matrix with differing degrees of vascularization[9,11].

Many other lesions such as lymphoplasmacyte-rich meningioma, schwannoma, lymphoma, and plasmacytoma have similar histological features as IMT. Lymphoma diagnosis can be ruled out by determining whether the cells are polyclonal. In addition, IMT is often closely associated with the dura, wherein the spindle cells are often mistaken for meningioma cells. This can be identified by concentric fibrosis in small vessels, which would not be present in meningioma[2,11,12].

Immunohistochemical analysis is an extremely important means of diagnosis of IMT. Fluorescence in situ hybridization with a probe flanking the ALK gene at 2p23 typically demonstrates a genetic rearrangement. While tumors with ALK gene rearrangements are readily considered a unique neoplastic category, histologically similar neoplastic lesions may lack this genetic alteration[6]. ALK expression is positive in nearly 50% of patients with IMT, especially in children, and is associated with local recurrence and distant metastasis[7]. However, in the literature we reviewed, only about 25% of cases were positive for ALK expression.

All other immunohistochemical markers are equally important. Spindle cells have the immunohistochemical characteristics of myofibroblasts and often express vimentin and smooth muscle actin[12]. Meningioma also shows infiltration by fibrous ground tissue and mononuclear cells, but the finding of meningeal whorls and positive exponential moving average were not observed in IMT-CNS[11]. S-100 is used to differentiate Rosai-Dorfman disease.

In recent years, IgG4 and programmed death receptor-1 have been proposed as markers to assist the diagnosis and treatment of IMT. IgG4-associated IMT was first detected in masses at sites other than the CNS. Some are part of a systemic disorder known as IgG4-related sclerosing disease. We found that intracranial IMTs had similar characteristics with IgG4-associated IMTs, except for the absence of granulomas and reactive lymphatic follicles<sup>[2]</sup>. Therefore, IgG4 may be useful for the diagnosis of IMT. Unfortunately, serum IgG4 levels have not been measured for most reported cases to date.

Cottrell et al[21] recently studied the relationship between programmed cell death ligand 1 expression and IMT. They found that in IMT programmed cell death ligand 1 is highly expressed in both tumor and immune cells and that it was also commonly expressed in ALK-negative cases (88%), whereas adaptive programmed cell death ligand 1 expression was present in the majority of tumors.

Our review of previous cases showed that immune-related mechanisms play an important role in the pathogenesis of IMT; thus, we should aim to detect the levels of relevant antibodies in the serum and cerebrospinal fluid as well as measure the erythrocyte sedimentation rate and other laboratory indicators to assist in the diagnosis of IMT.

#### Treatment strategy

Due to the rarity of IMT-CNS, no gold standard therapy has yet been identified. Currently, complete surgical resection of the tumor is the preferred treatment. In addition to surgical treatment, several other treatment options have emerged in recent years. Many researchers have treated IMT with corticosteroids for autoimmune pathogenesis, and the clinical and radioimaging findings showed improvement in most cases after such treatment [2,3,9,12]. Radiation therapy is rarely used in the treatment of IMT, and its efficacy is uncertain[12]. Several reportedly active regimens have been described in the literature, including vincristine plus methotrexate, vincristine plus etoposide, cisplatin/carboplatin-based regimes, ifosfamide-based regimens, and doxorubicin in combination with other drugs and taxanes[22-24].

Mycophenolate mofetil is commonly used in the treatment of IgG4-related immune diseases, and Moss *et al*[14] proposed the use of mycophenolate mofetil in IgG4-positive IMT patients. In 2 cases, the side effects of corticosteroids were greatly improved after mycophenolate mofetil treatment, and clinical symptoms were relieved. In some cases, rituximab also helped shrink the IMT and improve the patient's symptoms[4]. The exact mechanism of action of rituximab is unknown, but it is believed to induce apoptosis via complement and antibody-dependent cell-mediated cytotoxicity[25].

#### Risk of postoperative recurrence

Although IMT is a benign disease, the risk of recurrence is high[11]. The histological features of the recurrent tumor have been consistent with IMT. However, the morphology of the recurrent tumor showed a more sarcomatous pattern[26]. In this review, we sought to identity the high-risk factors related to IMT recurrence. We divided 47 cases of IMT-CNS into groups according to the resection method, ALK expression, and sex and counted the number of cases with tumor recurrence in each group. Seven patients treated with total tumor resection experienced recurrence within 5 years, and 5



Table 2 Recurrence of inflammatory myofibroblastic-tumor-central nervous system in the 49 reviewed patients according to surgica	1
treatment type	

Surgery type	Recurrence in 5 yr	No recurrence in 5 yr	Total			
GTR	1	13	14			
STR	1	5	6			
Total	2	18	20			

Null hypothesis: the method of tumor resection has an effect on tumor recurrence, P > 0.05. The method of resection did not affect whether the inflammatory myofibroblastic tumor recurred. GTR: Gross total resection; STR: Subtotal resection.

Table 3 Recurrence of inflammatory myofibroblastic-tumor-central nervous in the 49 reviewed patients according to results for immunohistochemical staining of anaplastic lymphoma kinase					
Staining result	Recurrence in 5 yr	No recurrence in 5 yr	Total		
ALK (+)	6	4	10		
ALK (-)	1	13	14		
Total	7	17	24		

Null hypothesis: the expression of anaplastic lymphoma kinase has an influence on tumor recurrence. P < 0.05. The expression of anaplastic lymphoma kinase affects the recurrence of inflammatory myofibroblastic tumors. ALK: Anaplastic lymphoma kinase.

> patients with subtotal tumor resection experienced recurrence. Postoperative immunohistochemistry showed that only 1 ALK-positive case did not experience recurrence within 5 years, while only 1 ALKnegative case experienced recurrence within 5 years. We applied the Fisher exact probability method to analyze these data, using SPSS software (version 23.0; IBM Corp., Armonk, NY, United States). We found that ALK expression had an effect on recurrence of IMT-CNS (P < 0.05; Table 2).

> The expression of some immunohistochemical factors is related to drug sensitivity, which affects disease prognosis[11,19]. In general, gross total resection should be used as a surgical target. Interestingly, statistical analysis showed that the method of resection had no effect on the recurrence of IMT (P > 0.05; Table 3). We think this may be related to the fact that IMT is a low-grade aggressive tumor. However, we should still use total resection as the first option whenever possible. Immunohistochemistry and other data should be used to determine the follow-up treatment to reduce disease recurrence. Finally, we believe that as our understanding of IMT continues to grow, a prognosis based on the biological profile of tumors is possible.

#### CONCLUSION

Intracranial IMT is a very rare disease. We summarized and analyzed 49 cases of intracranial IMT and found that the incidence rates in male and female patients were similar. Headache is the most common initial symptom in clinical manifestations, but it is also closely related to the location of tumor growth. MRI is an important means of IMT diagnosis, and expression of ALK as an important molecular marker of IMT has been widely used in recent years. Complete surgical resection of the tumor is the preferred treatment, and continued treatment after operation cannot be ignored. For tumors that are difficult to remove, glucocorticoids, radiotherapy, and other treatments can be administered to limit tumor growth or even eliminate tumors. ALK expression was closely related to the recurrence of IMT. Further analyses of more cases of IMT-CNS and long-term follow-up investigations are needed. We believe our case report provides an additional reference for clinicians for the pathogenetic diagnosis and treatment of IMT-CNS.

#### FOOTNOTES

Author contributions: Su ZJ, Guo ZS, and Wan HT designed the study, collected and analyzed the data, explained the data, drafted the manuscript, and performed the literature review; Hong XY performed the surgery and contributed to preoperative and postoperative imaging and analysis and interpretation of pathological and immunohistochemical results; Su ZJ revised the language of the manuscript and made critical revisions to finalize the version submitted;



Hong XY provided critical expertise, approved the submitted article, and agreed to be responsible for all aspects of the work; All authors made read and approved the submitted version.

Informed consent statement: Informed written consent was obtained from the patient and her family for publication of this report and any accompanying images.

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is noncommercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

#### Country/Territory of origin: China

ORCID number: Zhen-Jin Su 0000-0001-9695-7402; Xin-Yu Hong 0000-0002-6939-3055.

S-Editor: Liu GL L-Editor: Filipodia P-Editor: Liu GL

#### REFERENCES

- 1 Jeon YK, Chang KH, Suh YL, Jung HW, Park SH. Inflammatory myofibroblastic tumor of the central nervous system: clinicopathologic analysis of 10 cases. J Neuropathol Exp Neurol 2005; 64: 254-259 [PMID: 15804057 DOI: 10.1093/jnen/64.3.254]
- 2 Lui PC, Fan YS, Wong SS, Chan AN, Wong G, Chau TK, Tse GM, Cheng Y, Poon WS, Ng HK. Inflammatory pseudotumors of the central nervous system. Hum Pathol 2009; 40: 1611-1617 [PMID: 19656549 DOI: 10.1016/j.humpath.2009.04.016]
- McKinney AM, Short J, Lucato L, SantaCruz K, McKinney Z, Kim Y. Inflammatory myofibroblastic tumor of the orbit with associated enhancement of the meninges and multiple cranial nerves. AJNR Am J Neuroradiol 2006; 27: 2217-2220 [PMID: 17110698]
- 4 Patel A, Kocoglu MH, Kaul A. Therapeutic strategies for durable response in plasma cell granulomas in the central nervous system. Ann Hematol 2019; 98: 1027-1029 [PMID: 30178192 DOI: 10.1007/s00277-018-3490-7]
- Wang X, Chen Y, Wu X, Zhang H. Intracranial Inflammatory Myofibroblastic Tumor with Negative Expression of Anaplastic Lymphoma Kinase: A Case Report and Review of the Literature. World Neurosurg 2019; 125: 117-122 [PMID: 30735872 DOI: 10.1016/j.wneu.2019.01.155]
- Swain RS, Tihan T, Horvai AE, Di Vizio D, Loda M, Burger PC, Scheithauer BW, Kim GE. Inflammatory myofibroblastic tumor of the central nervous system and its relationship to inflammatory pseudotumor. Hum Pathol 2008; 39: 410-419 [PMID: 18261625 DOI: 10.1016/j.humpath.2007.07.012]
- Pascual-Gallego M, Yus-Fuertes M, Jorquera M, Gonzalez-Mat A, Ortega L, Martinez-Martinez A, Zimman H. Recurrent meningeal inflammatory myofibroblastic tumor: a case report and literature review. Neurol India 2013; 61: 644-649 [PMID: 24441334 DOI: 10.4103/0028-3886.125273]
- 8 Coffin CM, Watterson J, Priest JR, Dehner LP. Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases. Am J Surg Pathol 1995; 19: 859-872 [PMID: 7611533 DOI: 10.1097/00000478-199508000-00001]
- Buccoliero AM, Caldarella A, Santucci M, Ammannati F, Mennonna P, Taddei A, Taddei GL. Plasma cell granuloma--an enigmatic lesion: description of an extensive intracranial case and review of the literature. Arch Pathol Lab Med 2003; 127: e220-e223 [PMID: 12683907 DOI: 10.5858/2003-127-e220-PCGEL]
- 10 Roche PH, Figarella-Branger D, Pellet W. Mixed meningeal and brain plasma-cell granuloma: an example of an unusual evolution. Acta Neurochir (Wien) 2004; 146: 69-72; discussion 72 [PMID: 14740268 DOI: 10.1007/s00701-003-0153-8]
- Häusler M, Schaade L, Ramaekers VT, Doenges M, Heimann G, Sellhaus B. Inflammatory pseudotumors of the central 11 nervous system: report of 3 cases and a literature review. Hum Pathol 2003; 34: 253-262 [PMID: 12673560 DOI: 10.1053/hupa.2003.35]
- Saint-Blancard P, Harket A, Tine I, Daumas-Duport C, de Soultrait FR. [A rare lesion of the central nervous system: 12 inflammatory pseudotumor]. Neurochirurgie 2008; 54: 37-40 [PMID: 18280522 DOI: 10.1016/j.neuchi.2008.01.001]
- Buccoliero AM, Caldarella A, Santucci M, Ammannati F, Mennonna P, Taddei A, Taddei GL. Plasma cell granuloma--an 13 enigmatic lesion: description of an extensive intracranial case and review of the literature. Arch Pathol Lab Med 2003; 127: e220-e223 [PMID: 12683907 DOI: 10.1038/sj.sc.3101271]
- 14 Moss HE, Mejico LJ, de la Roza G, Coyne TM, Galetta SL, Liu GT. IgG4-related inflammatory pseudotumor of the central nervous system responsive to mycophenolate mofetil. J Neurol Sci 2012; 318: 31-35 [PMID: 22546342 DOI: 10.1016/j.jns.2012.04.010]
- Kuang PD, Li QH, Liu ZY, Tang JL, Dong F, Wang Y, Zhu XL. Inflammatory pseudotumor of the pineal region: First



reported case. Oncol Lett 2016; 11: 2127-2130 [PMID: 26998134 DOI: 10.3892/ol.2016.4212]

- 16 Han MH, Chi JG, Kim MS, Chang KH, Kim KH, Yeon KM, Han MC. Fibrosing inflammatory pseudotumors involving the skull base: MR and CT manifestations with histopathologic comparison. AJNR Am J Neuroradiol 1996; 17: 515-521 [PMID: 8881247]
- Nakayama K, Inoue Y, Aiba T, Kono K, Wakasa K, Yamada R. Unusual CT and MR findings of inflammatory 17 pseudotumor in the parapharyngeal space: case report. AJNR Am J Neuroradiol 2001; 22: 1394-1397 [PMID: 11498435]
- 18 Kolenc D, Dotlić S, Adamec I, Zadro I, Stambuk C, Ozretić D, Habek M. Isolated plasma cell granuloma of the meninges. Neurol Sci 2013; 34: 2245-2247 [PMID: 23812797 DOI: 10.1007/s10072-013-1488-4]
- 19 Denis DJ, Elayoubi K, Weil AG, Berthelet F, Bojanowski MW. Inflammatory myofibroblastic tumors of the central nervous system that express anaplastic lymphoma kinase have a high recurrence rate. Surg Neurol Int 2013; 4: 70 [PMID: 23776756 DOI: 10.4103/2152-7806.112614]
- 20 Miyahara K, Fujitsu K, Yagishita S, Takemoto Y, Ichikawa T, Matsunaga S, Takeda Y, Niino H, Shiina T. Inflammatory pseudotumor of the choroid plexus. Case report. J Neurosurg 2008; 108: 365-369 [PMID: 18240936 DOI: 10.3171/JNS/2008/108/2/0365
- Cottrell TR, Duong AT, Gocke CD, Xu H, Ogurtsova A, Taube JM, Belchis DA. PD-L1 expression in inflammatory 21 myofibroblastic tumors. Mod Pathol 2018; 31: 1155-1163 [PMID: 29449680 DOI: 10.1038/s41379-018-0034-6]
- 22 Kovach SJ, Fischer AC, Katzman PJ, Salloum RM, Ettinghausen SE, Madeb R, Koniaris LG. Inflammatory myofibroblastic tumors. J Surg Oncol 2006; 94: 385-391 [PMID: 16967468 DOI: 10.1002/jso.20516]
- 23 Dishop MK, Warner BW, Dehner LP, Kriss VM, Greenwood MF, Geil JD, Moscow JA. Successful treatment of inflammatory myofibroblastic tumor with malignant transformation by surgical resection and chemotherapy. J Pediatr Hematol Oncol 2003; 25: 153-158 [PMID: 12571469 DOI: 10.1097/00043426-200302000-00014]
- 24 Trojan A, Stallmach T, Kollias S, Pestalozzi BC. Inflammatory myofibroblastic tumor with CNS involvement. Onkologie 2001; 24: 368-372 [PMID: 11574765 DOI: 10.1159/000055109]
- 25 Garcia BA, Tinsley S, Schellenberger T, Bobustuc GC. Recurrent inflammatory pseudotumor of the jaw with perineural intracranial invasion demonstrating sustained response to Rituximab. Med Oncol 2012; 29: 2452-2455 [PMID: 22161155 DOI: 10.1007/s12032-011-0128-1]
- 26 Chuah YY, Tashi T, Shy CG, Shyu JS, Dong MJ, Hsueh EJ. Intracranial Inflammatory Myofibroblastic Tumor with Sarcomatous Local Recurrence. World Neurosurg 2016; 93: 484.e1-484.e4 [PMID: 27465420 DOI: 10.1016/j.wneu.2016.07.060]
- 27 de Oliveira RS, Amato MC, Brassesco MS, Valera ET, Jucá CE, Neder L, Tone LG, Machado HR. Clinical and cytogenetic analysis of an intracranial inflammatory myofibroblastic tumor induced by a ventriculoperitoneal shunt. J Neurosurg Pediatr 2009; 4: 372-377 [PMID: 19795970 DOI: 10.3171/2009.5.PEDS0958]
- 28 Kato K, Moteki Y, Nakagawa M, Kadoyama S, Ujiie H. Inflammatory myofibroblastic tumor of the cerebellar hemisphere--case report. Neurol Med Chir (Tokyo) 2011; 51: 79-81 [PMID: 21273753 DOI: 10.2176/nmc.51.79]





# Published by Baishideng Publishing Group Inc 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-3991568 E-mail: bpgoffice@wjgnet.com Help Desk: https://www.f6publishing.com/helpdesk https://www.wjgnet.com

